One pill instead of three? HIV combo tablet put to the test
NCT ID NCT07753902
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial asks whether a single tablet combining three HIV medications (ACC017, emtricitabine, and tenofovir alafenamide) is absorbed by the body just as well as taking the same drugs separately. Healthy adult volunteers will receive both versions in a random order under fasting conditions, and researchers will compare drug levels in the blood. The goal is to see if the combination tablet is equivalent and safe, which could make HIV treatment simpler.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADC118 tablets (a combination of ACC017, emtricitabine, and tenofovir alafenamide fumarate)
- What this could lead to
- If the combination tablet is shown to be equivalent, it could simplify HIV treatment by reducing the number of pills people need to take.
- What could go wrong
- This is an early-stage study in healthy volunteers, not people with HIV. The results may not reflect real-world effectiveness, and the drug could still cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chizhou People's Hospital
Chizhou, Anhui, 247100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.